胃腸薬市場：タイプ別、疾患タイプ別、投与経路別、流通チャネル別、エンドユーザー別-2025-2030年の世界予測

胃腸薬市場は、2023年に572億6,000万米ドルと評価され、2024年には600億6,000万米ドルに達すると予測され、CAGR 4.97％で成長し、2030年には804億7,000万米ドルに達すると予測されています。

胃腸薬市場には、制酸剤、プロトンポンプ阻害剤、緩下剤、下痢止め、抗ヒスタミン剤など、消化管の障害を緩和するための薬理学的治療が幅広く含まれています。これらの薬剤の必要性は、消化器疾患の有病率の上昇、腸内環境の悪化につながるライフスタイルの変化、消化器疾患にかかりやすくなる高齢化によって強調されています。これらの薬剤は、GERD、クローン病、過敏性腸症候群など多様な症状に対応し、処方薬と市販薬の両分野で応用されています。エンドユーザーは病院や診療所から在宅医療まで幅広く、効果的な治療ソリューションに対する需要の高まりに後押しされています。

市場成長は、ヘルスケア意識の高まり、製薬研究の進展、医療施設へのアクセス向上による新興市場での需要急増の影響を大きく受けています。特に生物学的製剤や個別化医療の分野では、新たな治療オプションが進化し続けているため、治療機会が拡大しています。さらに、デジタルヘルスの進歩とeコマース・プラットフォームは、市場浸透と消費者エンゲージメントのための新たな道を開いています。しかし、厳しい規制基準、副作用の可能性、研究開発コストの高さなどの課題が障害となっています。特に新興国市場では市場が飽和状態にあり、ジェネリック医薬品の競合もまた、成長を複雑なものにしています。

将来性のある革新的な研究分野には、微生物を利用した治療法、植物由来の代替医薬品、ナノメディシンなどのドラッグデリバリーシステムの進歩などがあります。こうした技術革新を取り入れることで、より的を絞った効果的な治療が可能になります。市場はダイナミックな性質を示し、新規治療薬の着実な流入に加え、消化管の病態生理学の理解を深めることを目的とした産学共同研究が活発に行われています。企業は、アンメットニーズに焦点を当てた研究開発への投資、規制当局との連携によるパスウェイの効率化、デジタルプラットフォームの活用による認知・流通の促進を行い、新興地域における大きな可能性を活用することで、市場の抑制要因を克服し、持続的な成長を促進することが推奨されます。

市場力学：急速に進化する胃腸薬市場の主要市場インサイトを公開

胃腸薬市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 世界の胃腸障害の有病率の増加
  • 胃腸の健康と利用可能な治療に関する教育キャンペーン
  • 健康保険の適用範囲と償還方針の好意的な変更
• 市場抑制要因
  • 医薬品製造に必要な原材料供給の混乱
• 市場機会
  • 消化器疾患治療用の新規治療薬の政府承認
  • 革新的な製剤とデリバリーシステムを目指した研究開発の継続
• 市場の課題
  • 胃腸薬やサプリメントに伴う副作用

ポーターのファイブフォース：胃腸薬市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：胃腸薬市場における外部からの影響の把握

外部マクロ環境要因は、胃腸薬市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析胃腸薬市場における競合情勢の把握

胃腸薬市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的な意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス胃腸薬市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、胃腸薬市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によりベンダーを明確かつ的確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨胃腸薬市場における成功への道筋を描く

胃腸薬市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を検討することで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大の可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品上市、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 世界中で胃腸疾患の罹患率が増加
    • 胃腸の健康と利用可能な治療法に関する教育キャンペーン
    • 健康保険の適用範囲と払い戻し方針の好ましい変更
  • 抑制要因
    • 医薬品製造に必要な原材料の供給の混乱
  • 機会
    • 胃腸障害治療のための新治療薬の政府承認
    • 革新的な医薬品製剤と送達システムを目指した継続的な研究開発
  • 課題
    • 胃腸薬やサプリメントに伴う副作用
• 市場セグメンテーション分析
  • タイプ：健康志向の消費者の増加に伴い、栄養補助食品の使用が増加している
  • エンドユーザー：患者の初期治療および継続的な管理計画の一環として、病院や診療所全体で胃腸薬の大きな可能性
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 胃腸薬市場：タイプ別

• 栄養補助食品
• 薬物
  • 制酸剤
  • 下痢止め薬
  • 制吐剤
  • H2ブロッカー
  • 下剤
  • プロトンポンプ阻害剤

第7章 胃腸薬市場：疾患タイプ別

• 便秘
• 下痢
• 胃食道逆流症
• 炎症性腸疾患
• 過敏性腸症候群
• 消化性潰瘍

第8章 胃腸薬市場：投与経路別

• オーラル
• 非経口
• 直腸

第9章 胃腸薬市場：流通チャネル別

• オフライン薬局
• オンライン薬局

第10章 胃腸薬市場：エンドユーザー別

• ホームケア
• 病院・クリニック

第11章 南北アメリカの胃腸薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第12章 アジア太平洋地域の胃腸薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第13章 欧州・中東・アフリカの胃腸薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第14章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • Calm & Focusのイントロダクション：PLT Health SolutionsによるZembrinとGABAベースの栄養補助食品
  • デザインズ・フォー・ヘルスが革新的な女性の健康のためのプロバイオティクスを発売
  • ターゲットストアでワンダーベリーの限定フレーバー制酸剤をイントロダクション
• 戦略分析と提言

企業一覧

• Abbott Laboratories
• American Health
• Amway Corporation
• Archer-Daniels-Midland Company
• ARKOPHARMA Laboratories, Company Limited
• Bayer AG
• Biomedical Research Laboratories, LLC
• DuPont de Nemours, Inc.
• Dymatize Enterprises LLC
• FANCL Corporation
• Glanbia PLC
• GlaxoSmithKline PLC
• Herbalife Nutrition Ltd.
• Himalaya Wellness Company
• Nature's Sunshine Products, Inc.
• Nestle S.A
• Nutraceutical International Corporation
• NutraScience Labs
• Otsuka Holdings Co. Ltd.
• Pfizer Inc.
• Pragati Biocare Pvt. Ltd.,
• Procter & Gamble Health Limited
• Pure Encapsulations, LLC.
• Sabinsa Corporation
• Sanofi S.A.

LIST OF FIGURES

• FIGURE 1. GASTROINTESTINAL AGENTS MARKET RESEARCH PROCESS
• FIGURE 2. GASTROINTESTINAL AGENTS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 15. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. AMERICAS GASTROINTESTINAL AGENTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. AMERICAS GASTROINTESTINAL AGENTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. UNITED STATES GASTROINTESTINAL AGENTS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 19. UNITED STATES GASTROINTESTINAL AGENTS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. ASIA-PACIFIC GASTROINTESTINAL AGENTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. ASIA-PACIFIC GASTROINTESTINAL AGENTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL AGENTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 23. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL AGENTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 24. GASTROINTESTINAL AGENTS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 25. GASTROINTESTINAL AGENTS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. GASTROINTESTINAL AGENTS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. GASTROINTESTINAL AGENTS MARKET DYNAMICS
• TABLE 7. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY DIETARY SUPPLEMENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY DRUGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ANTACIDS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ANTI-DIARRHEAL AGENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ANTI-EMETICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY H2 BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY LAXATIVES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY PROTON PUMP INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY CONSTIPATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY DIARRHEA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY GASTROESOPHAGEAL REFLUX DISEASE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY IRRITABLE BOWEL SYNDROME, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY PEPTIC ULCER DISEASE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY RECTAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY OFFLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 31. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 32. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY HOMECARE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 33. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 34. AMERICAS GASTROINTESTINAL AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 35. AMERICAS GASTROINTESTINAL AGENTS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 36. AMERICAS GASTROINTESTINAL AGENTS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 37. AMERICAS GASTROINTESTINAL AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 38. AMERICAS GASTROINTESTINAL AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 39. AMERICAS GASTROINTESTINAL AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 40. AMERICAS GASTROINTESTINAL AGENTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 41. ARGENTINA GASTROINTESTINAL AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 42. ARGENTINA GASTROINTESTINAL AGENTS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 43. ARGENTINA GASTROINTESTINAL AGENTS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 44. ARGENTINA GASTROINTESTINAL AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 45. ARGENTINA GASTROINTESTINAL AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 46. ARGENTINA GASTROINTESTINAL AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 47. BRAZIL GASTROINTESTINAL AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 48. BRAZIL GASTROINTESTINAL AGENTS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 49. BRAZIL GASTROINTESTINAL AGENTS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 50. BRAZIL GASTROINTESTINAL AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 51. BRAZIL GASTROINTESTINAL AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 52. BRAZIL GASTROINTESTINAL AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 53. CANADA GASTROINTESTINAL AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 54. CANADA GASTROINTESTINAL AGENTS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 55. CANADA GASTROINTESTINAL AGENTS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 56. CANADA GASTROINTESTINAL AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 57. CANADA GASTROINTESTINAL AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 58. CANADA GASTROINTESTINAL AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 59. MEXICO GASTROINTESTINAL AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 60. MEXICO GASTROINTESTINAL AGENTS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 61. MEXICO GASTROINTESTINAL AGENTS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 62. MEXICO GASTROINTESTINAL AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 63. MEXICO GASTROINTESTINAL AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 64. MEXICO GASTROINTESTINAL AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 65. UNITED STATES GASTROINTESTINAL AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 66. UNITED STATES GASTROINTESTINAL AGENTS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 67. UNITED STATES GASTROINTESTINAL AGENTS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 68. UNITED STATES GASTROINTESTINAL AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 69. UNITED STATES GASTROINTESTINAL AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 70. UNITED STATES GASTROINTESTINAL AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 71. UNITED STATES GASTROINTESTINAL AGENTS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 72. ASIA-PACIFIC GASTROINTESTINAL AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 73. ASIA-PACIFIC GASTROINTESTINAL AGENTS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 74. ASIA-PACIFIC GASTROINTESTINAL AGENTS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 75. ASIA-PACIFIC GASTROINTESTINAL AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 76. ASIA-PACIFIC GASTROINTESTINAL AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 77. ASIA-PACIFIC GASTROINTESTINAL AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 78. ASIA-PACIFIC GASTROINTESTINAL AGENTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 79. AUSTRALIA GASTROINTESTINAL AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 80. AUSTRALIA GASTROINTESTINAL AGENTS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 81. AUSTRALIA GASTROINTESTINAL AGENTS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 82. AUSTRALIA GASTROINTESTINAL AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 83. AUSTRALIA GASTROINTESTINAL AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 84. AUSTRALIA GASTROINTESTINAL AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 85. CHINA GASTROINTESTINAL AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 86. CHINA GASTROINTESTINAL AGENTS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 87. CHINA GASTROINTESTINAL AGENTS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 88. CHINA GASTROINTESTINAL AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 89. CHINA GASTROINTESTINAL AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 90. CHINA GASTROINTESTINAL AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 91. INDIA GASTROINTESTINAL AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 92. INDIA GASTROINTESTINAL AGENTS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 93. INDIA GASTROINTESTINAL AGENTS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 94. INDIA GASTROINTESTINAL AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 95. INDIA GASTROINTESTINAL AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 96. INDIA GASTROINTESTINAL AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 97. INDONESIA GASTROINTESTINAL AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 98. INDONESIA GASTROINTESTINAL AGENTS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 99. INDONESIA GASTROINTESTINAL AGENTS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 100. INDONESIA GASTROINTESTINAL AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 101. INDONESIA GASTROINTESTINAL AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 102. INDONESIA GASTROINTESTINAL AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 103. JAPAN GASTROINTESTINAL AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 104. JAPAN GASTROINTESTINAL AGENTS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 105. JAPAN GASTROINTESTINAL AGENTS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 106. JAPAN GASTROINTESTINAL AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 107. JAPAN GASTROINTESTINAL AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 108. JAPAN GASTROINTESTINAL AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 109. MALAYSIA GASTROINTESTINAL AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 110. MALAYSIA GASTROINTESTINAL AGENTS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 111. MALAYSIA GASTROINTESTINAL AGENTS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 112. MALAYSIA GASTROINTESTINAL AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 113. MALAYSIA GASTROINTESTINAL AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 114. MALAYSIA GASTROINTESTINAL AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 115. PHILIPPINES GASTROINTESTINAL AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 116. PHILIPPINES GASTROINTESTINAL AGENTS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 117. PHILIPPINES GASTROINTESTINAL AGENTS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 118. PHILIPPINES GASTROINTESTINAL AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 119. PHILIPPINES GASTROINTESTINAL AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 120. PHILIPPINES GASTROINTESTINAL AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 121. SINGAPORE GASTROINTESTINAL AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 122. SINGAPORE GASTROINTESTINAL AGENTS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 123. SINGAPORE GASTROINTESTINAL AGENTS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 124. SINGAPORE GASTROINTESTINAL AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 125. SINGAPORE GASTROINTESTINAL AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 126. SINGAPORE GASTROINTESTINAL AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 127. SOUTH KOREA GASTROINTESTINAL AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 128. SOUTH KOREA GASTROINTESTINAL AGENTS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 129. SOUTH KOREA GASTROINTESTINAL AGENTS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 130. SOUTH KOREA GASTROINTESTINAL AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 131. SOUTH KOREA GASTROINTESTINAL AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 132. SOUTH KOREA GASTROINTESTINAL AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 133. TAIWAN GASTROINTESTINAL AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 134. TAIWAN GASTROINTESTINAL AGENTS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 135. TAIWAN GASTROINTESTINAL AGENTS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 136. TAIWAN GASTROINTESTINAL AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 137. TAIWAN GASTROINTESTINAL AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 138. TAIWAN GASTROINTESTINAL AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 139. THAILAND GASTROINTESTINAL AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 140. THAILAND GASTROINTESTINAL AGENTS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 141. THAILAND GASTROINTESTINAL AGENTS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 142. THAILAND GASTROINTESTINAL AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 143. THAILAND GASTROINTESTINAL AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 144. THAILAND GASTROINTESTINAL AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 145. VIETNAM GASTROINTESTINAL AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 146. VIETNAM GASTROINTESTINAL AGENTS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 147. VIETNAM GASTROINTESTINAL AGENTS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 148. VIETNAM GASTROINTESTINAL AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 149. VIETNAM GASTROINTESTINAL AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 150. VIETNAM GASTROINTESTINAL AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 151. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 152. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL AGENTS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 153. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL AGENTS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 154. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 155. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 156. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 157. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL AGENTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 158. DENMARK GASTROINTESTINAL AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 159. DENMARK GASTROINTESTINAL AGENTS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 160. DENMARK GASTROINTESTINAL AGENTS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 161. DENMARK GASTROINTESTINAL AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 162. DENMARK GASTROINTESTINAL AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 163. DENMARK GASTROINTESTINAL AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 164. EGYPT GASTROINTESTINAL AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 165. EGYPT GASTROINTESTINAL AGENTS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 166. EGYPT GASTROINTESTINAL AGENTS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 167. EGYPT GASTROINTESTINAL AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 168. EGYPT GASTROINTESTINAL AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 169. EGYPT GASTROINTESTINAL AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 170. FINLAND GASTROINTESTINAL AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 171. FINLAND GASTROINTESTINAL AGENTS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 172. FINLAND GASTROINTESTINAL AGENTS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 173. FINLAND GASTROINTESTINAL AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 174. FINLAND GASTROINTESTINAL AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 175. FINLAND GASTROINTESTINAL AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 176. FRANCE GASTROINTESTINAL AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 177. FRANCE GASTROINTESTINAL AGENTS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 178. FRANCE GASTROINTESTINAL AGENTS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 179. FRANCE GASTROINTESTINAL AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 180. FRANCE GASTROINTESTINAL AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 181. FRANCE GASTROINTESTINAL AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 182. GERMANY GASTROINTESTINAL AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 183. GERMANY GASTROINTESTINAL AGENTS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 184. GERMANY GASTROINTESTINAL AGENTS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 185. GERMANY GASTROINTESTINAL AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 186. GERMANY GASTROINTESTINAL AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 187. GERMANY GASTROINTESTINAL AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 188. ISRAEL GASTROINTESTINAL AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 189. ISRAEL GASTROINTESTINAL AGENTS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 190. ISRAEL GASTROINTESTINAL AGENTS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 191. ISRAEL GASTROINTESTINAL AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 192. ISRAEL GASTROINTESTINAL AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 193. ISRAEL GASTROINTESTINAL AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 194. ITALY GASTROINTESTINAL AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 195. ITALY GASTROINTESTINAL AGENTS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 196. ITALY GASTROINTESTINAL AGENTS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 197. ITALY GASTROINTESTINAL AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 198. ITALY GASTROINTESTINAL AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 199. ITALY GASTROINTESTINAL AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 200. NETHERLANDS GASTROINTESTINAL AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 201. NETHERLANDS GASTROINTESTINAL AGENTS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 202. NETHERLANDS GASTROINTESTINAL AGENTS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 203. NETHERLANDS GASTROINTESTINAL AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 204. NETHERLANDS GASTROINTESTINAL AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 205. NETHERLANDS GASTROINTESTINAL AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 206. NIGERIA GASTROINTESTINAL AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 207. NIGERIA GASTROINTESTINAL AGENTS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 208. NIGERIA GASTROINTESTINAL AGENTS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 209. NIGERIA GASTROINTESTINAL AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 210. NIGERIA GASTROINTESTINAL AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 211. NIGERIA GASTROINTESTINAL AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 212. NORWAY GASTROINTESTINAL AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 213. NORWAY GASTROINTESTINAL AGENTS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 214. NORWAY GASTROINTESTINAL AGENTS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 215. NORWAY GASTROINTESTINAL AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 216. NORWAY GASTROINTESTINAL AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 217. NORWAY GASTROINTESTINAL AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 218. POLAND GASTROINTESTINAL AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 219. POLAND GASTROINTESTINAL AGENTS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 220. POLAND GASTROINTESTINAL AGENTS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 221. POLAND GASTROINTESTINAL AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 222. POLAND GASTROINTESTINAL AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 223. POLAND GASTROINTESTINAL AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 224. QATAR GASTROINTESTINAL AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 225. QATAR GASTROINTESTINAL AGENTS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 226. QATAR GASTROINTESTINAL AGENTS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 227. QATAR GASTROINTESTINAL AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 228. QATAR GASTROINTESTINAL AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 229. QATAR GASTROINTESTINAL AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 230. RUSSIA GASTROINTESTINAL AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 231. RUSSIA GASTROINTESTINAL AGENTS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 232. RUSSIA GASTROINTESTINAL AGENTS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 233. RUSSIA GASTROINTESTINAL AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 234. RUSSIA GASTROINTESTINAL AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 235. RUSSIA GASTROINTESTINAL AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 236. SAUDI ARABIA GASTROINTESTINAL AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 237. SAUDI ARABIA GASTROINTESTINAL AGENTS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 238. SAUDI ARABIA GASTROINTESTINAL AGENTS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 239. SAUDI ARABIA GASTROINTESTINAL AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 240. SAUDI ARABIA GASTROINTESTINAL AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 241. SAUDI ARABIA GASTROINTESTINAL AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 242. SOUTH AFRICA GASTROINTESTINAL AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 243. SOUTH AFRICA GASTROINTESTINAL AGENTS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 244. SOUTH AFRICA GASTROINTESTINAL AGENTS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 245. SOUTH AFRICA GASTROINTESTINAL AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 246. SOUTH AFRICA GASTROINTESTINAL AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 247. SOUTH AFRICA GASTROINTESTINAL AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 248. SPAIN GASTROINTESTINAL AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 249. SPAIN GASTROINTESTINAL AGENTS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 250. SPAIN GASTROINTESTINAL AGENTS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 251. SPAIN GASTROINTESTINAL AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 252. SPAIN GASTROINTESTINAL AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 253. SPAIN GASTROINTESTINAL AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 254. SWEDEN GASTROINTESTINAL AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 255. SWEDEN GASTROINTESTINAL AGENTS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 256. SWEDEN GASTROINTESTINAL AGENTS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 257. SWEDEN GASTROINTESTINAL AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 258. SWEDEN GASTROINTESTINAL AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 259. SWEDEN GASTROINTESTINAL AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 260. SWITZERLAND GASTROINTESTINAL AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 261. SWITZERLAND GASTROINTESTINAL AGENTS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 262. SWITZERLAND GASTROINTESTINAL AGENTS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 263. SWITZERLAND GASTROINTESTINAL AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 264. SWITZERLAND GASTROINTESTINAL AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 265. SWITZERLAND GASTROINTESTINAL AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 266. TURKEY GASTROINTESTINAL AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 267. TURKEY GASTROINTESTINAL AGENTS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 268. TURKEY GASTROINTESTINAL AGENTS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 269. TURKEY GASTROINTESTINAL AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 270. TURKEY GASTROINTESTINAL AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 271. TURKEY GASTROINTESTINAL AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 272. UNITED ARAB EMIRATES GASTROINTESTINAL AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 273. UNITED ARAB EMIRATES GASTROINTESTINAL AGENTS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 274. UNITED ARAB EMIRATES GASTROINTESTINAL AGENTS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 275. UNITED ARAB EMIRATES GASTROINTESTINAL AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 276. UNITED ARAB EMIRATES GASTROINTESTINAL AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 277. UNITED ARAB EMIRATES GASTROINTESTINAL AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 278. UNITED KINGDOM GASTROINTESTINAL AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 279. UNITED KINGDOM GASTROINTESTINAL AGENTS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 280. UNITED KINGDOM GASTROINTESTINAL AGENTS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 281. UNITED KINGDOM GASTROINTESTINAL AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 282. UNITED KINGDOM GASTROINTESTINAL AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 283. UNITED KINGDOM GASTROINTESTINAL AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 284. GASTROINTESTINAL AGENTS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 285. GASTROINTESTINAL AGENTS MARKET, FPNV POSITIONING MATRIX, 2023

The Gastrointestinal Agents Market was valued at USD 57.26 billion in 2023, expected to reach USD 60.06 billion in 2024, and is projected to grow at a CAGR of 4.97%, to USD 80.47 billion by 2030.

The gastrointestinal agents market encompasses a wide array of pharmacological treatments designed to alleviate disorders of the digestive tract, including antacids, proton pump inhibitors, laxatives, anti-diarrheals, and antihistamines for gastrointestinal use. The necessity of these agents is underscored by the rising prevalence of digestive disorders, lifestyle changes that contribute to poor gut health, and the aging population which is more susceptible to gastrointestinal ailments. These agents find applications in both prescription and over-the-counter segments, catering to diverse conditions such as GERD, Crohn's disease, irritable bowel syndrome, and more. End-users predominantly range from hospitals and clinics to home care settings, driven by the escalating demand for effective treatment solutions.

Market growth is significantly influenced by increased healthcare awareness, advancing pharmaceutical research, and burgeoning demand in emerging markets due to better access to healthcare facilities. Opportunities flourish particularly in biologic and personalized medicine sectors, as novel treatment options continue to evolve. Moreover, digital health advancements and e-commerce platforms are unlocking new avenues for market penetration and consumer engagement. However, challenges including stringent regulatory standards, potential side effects, and high R&D costs pose hindrances. A saturated market, particularly in developed regions, and generics competition also add layers of complexity to growth.

Innovation and research areas with substantial promise include microbiome-based therapies, plant-derived and alternative medicinal products, and advancements in drug delivery systems such as nanomedicine. Embracing these innovations can lead to more targeted and effective therapies. The market exhibits a dynamic nature, with a steady influx of novel therapeutics complemented by substantial industry-academia collaborations aimed at better understanding gastrointestinal pathophysiology. Companies are recommended to invest in R&D focused on unmet needs, engage with regulatory bodies to streamline pathways, and leverage digital platforms for awareness and distribution to capitalize on the massive potential in emerging regions, thereby overcoming market limitations and driving sustainable growth.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Gastrointestinal Agents Market

The Gastrointestinal Agents Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Growing prevalence of gastrointestinal disorders across the globe
  • Educational campaigns about gastrointestinal health and available treatments
  • Favorable changes in health insurance coverage and reimbursement policies
• Market Restraints
  • Disruptions in the supply of raw materials required for drug manufacturing
• Market Opportunities
  • Government approvals for new therapeutic agents to treat gastrointestinal disorders
  • Ongoing research and development aimed at innovative drug formulations and delivery systems
• Market Challenges
  • Side effects associated with gastrointestinal drugs and supplements

Porter's Five Forces: A Strategic Tool for Navigating the Gastrointestinal Agents Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Gastrointestinal Agents Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Gastrointestinal Agents Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Gastrointestinal Agents Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Gastrointestinal Agents Market

A detailed market share analysis in the Gastrointestinal Agents Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Gastrointestinal Agents Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Gastrointestinal Agents Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Gastrointestinal Agents Market

A strategic analysis of the Gastrointestinal Agents Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Gastrointestinal Agents Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, American Health, Amway Corporation, Archer-Daniels-Midland Company, ARKOPHARMA Laboratories, Company Limited, Bayer AG, Biomedical Research Laboratories, LLC, DuPont de Nemours, Inc., Dymatize Enterprises LLC, FANCL Corporation, Glanbia PLC, GlaxoSmithKline PLC, Herbalife Nutrition Ltd., Himalaya Wellness Company, Nature's Sunshine Products, Inc., Nestle S.A, Nutraceutical International Corporation, NutraScience Labs, Otsuka Holdings Co. Ltd., Pfizer Inc., Pragati Biocare Pvt. Ltd.,, Procter & Gamble Health Limited, Pure Encapsulations, LLC., Sabinsa Corporation, and Sanofi S.A..

Market Segmentation & Coverage

This research report categorizes the Gastrointestinal Agents Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Type, market is studied across Dietary Supplements and Drugs. The Drugs is further studied across Antacids, Anti-diarrheal Agents, Anti-emetics, H2 Blockers, Laxatives, and Proton Pump Inhibitors.
• Based on Disease Type, market is studied across Constipation, Diarrhea, Gastroesophageal Reflux Disease, Inflammatory Bowel Disease, Irritable Bowel Syndrome, and Peptic Ulcer Disease.
• Based on Route of Administration, market is studied across Oral, Parenteral, and Rectal.
• Based on Distribution Channel, market is studied across Offline Pharmacies and Online Pharmacies.
• Based on End-User, market is studied across Homecare and Hospitals & Clinics.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Growing prevalence of gastrointestinal disorders across the globe
    • 5.1.1.2. Educational campaigns about gastrointestinal health and available treatments
    • 5.1.1.3. Favorable changes in health insurance coverage and reimbursement policies
  • 5.1.2. Restraints
    • 5.1.2.1. Disruptions in the supply of raw materials required for drug manufacturing
  • 5.1.3. Opportunities
    • 5.1.3.1. Government approvals for new therapeutic agents to treat gastrointestinal disorders
    • 5.1.3.2. Ongoing research and development aimed at innovative drug formulations and delivery systems
  • 5.1.4. Challenges
    • 5.1.4.1. Side effects associated with gastrointestinal drugs and supplements
• 5.2. Market Segmentation Analysis
  • 5.2.1. Type: Growing usage of dietary supplements with an increasing number of health-conscious consumers
  • 5.2.2. End-User: High potential of gastrointestinal agents across hospitals & clinics as part of initial treatment and ongoing management plans for patients
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Gastrointestinal Agents Market, by Type

• 6.1. Introduction
• 6.2. Dietary Supplements
• 6.3. Drugs
  • 6.3.1. Antacids
  • 6.3.2. Anti-diarrheal Agents
  • 6.3.3. Anti-emetics
  • 6.3.4. H2 Blockers
  • 6.3.5. Laxatives
  • 6.3.6. Proton Pump Inhibitors

7. Gastrointestinal Agents Market, by Disease Type

• 7.1. Introduction
• 7.2. Constipation
• 7.3. Diarrhea
• 7.4. Gastroesophageal Reflux Disease
• 7.5. Inflammatory Bowel Disease
• 7.6. Irritable Bowel Syndrome
• 7.7. Peptic Ulcer Disease

8. Gastrointestinal Agents Market, by Route of Administration

• 8.1. Introduction
• 8.2. Oral
• 8.3. Parenteral
• 8.4. Rectal

9. Gastrointestinal Agents Market, by Distribution Channel

• 9.1. Introduction
• 9.2. Offline Pharmacies
• 9.3. Online Pharmacies

10. Gastrointestinal Agents Market, by End-User

• 10.1. Introduction
• 10.2. Homecare
• 10.3. Hospitals & Clinics

11. Americas Gastrointestinal Agents Market

• 11.1. Introduction
• 11.2. Argentina
• 11.3. Brazil
• 11.4. Canada
• 11.5. Mexico
• 11.6. United States

12. Asia-Pacific Gastrointestinal Agents Market

• 12.1. Introduction
• 12.2. Australia
• 12.3. China
• 12.4. India
• 12.5. Indonesia
• 12.6. Japan
• 12.7. Malaysia
• 12.8. Philippines
• 12.9. Singapore
• 12.10. South Korea
• 12.11. Taiwan
• 12.12. Thailand
• 12.13. Vietnam

13. Europe, Middle East & Africa Gastrointestinal Agents Market

• 13.1. Introduction
• 13.2. Denmark
• 13.3. Egypt
• 13.4. Finland
• 13.5. France
• 13.6. Germany
• 13.7. Israel
• 13.8. Italy
• 13.9. Netherlands
• 13.10. Nigeria
• 13.11. Norway
• 13.12. Poland
• 13.13. Qatar
• 13.14. Russia
• 13.15. Saudi Arabia
• 13.16. South Africa
• 13.17. Spain
• 13.18. Sweden
• 13.19. Switzerland
• 13.20. Turkey
• 13.21. United Arab Emirates
• 13.22. United Kingdom

14. Competitive Landscape

• 14.1. Market Share Analysis, 2023
• 14.2. FPNV Positioning Matrix, 2023
• 14.3. Competitive Scenario Analysis
  • 14.3.1. Introduction of Calm & Focus: A Zembrin and GABA-Based Dietary Supplement by PLT Health Solutions
  • 14.3.2. Innovative Women's Health Probiotics Launched by Designs for Health
  • 14.3.3. Market Introduction of Wonderbelly Antacid with Exclusive Flavor at Target Stores
• 14.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbott Laboratories
• 2. American Health
• 3. Amway Corporation
• 4. Archer-Daniels-Midland Company
• 5. ARKOPHARMA Laboratories, Company Limited
• 6. Bayer AG
• 7. Biomedical Research Laboratories, LLC
• 8. DuPont de Nemours, Inc.
• 9. Dymatize Enterprises LLC
• 10. FANCL Corporation
• 11. Glanbia PLC
• 12. GlaxoSmithKline PLC
• 13. Herbalife Nutrition Ltd.
• 14. Himalaya Wellness Company
• 15. Nature's Sunshine Products, Inc.
• 16. Nestle S.A
• 17. Nutraceutical International Corporation
• 18. NutraScience Labs
• 19. Otsuka Holdings Co. Ltd.
• 20. Pfizer Inc.
• 21. Pragati Biocare Pvt. Ltd.,
• 22. Procter & Gamble Health Limited
• 23. Pure Encapsulations, LLC.
• 24. Sabinsa Corporation
• 25. Sanofi S.A.